

Datasheet: C12CA

BATCH NUMBER 166867

Description:	BABY RABBIT COMPLEMENT
Name:	BABY RABBIT COMPLEMENT
Format:	Serum
Product Type:	Serum
Quantity:	2 ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Functional Assays (1)	▪			
Immunoassay	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

(1) This product is not sold as sterile but can be sterilized by filtration if necessary. It is preferable to dilute the complement to a final working concentration before filtration in order to minimize loss of volume.

Product Form	Baby rabbit serum - lyophilized
Reconstitution	Reconstitute with 2ml ice cold distilled water
Preservative Stabilisers	None present
Product Information	Baby rabbit complement serum preparation is intended for use as a source of rabbit complement for cytotoxicity assays.
Instructions For Use	Use within one hour of reconstitution, keeping on ice throughout.

References

1. De clerq, L. *et al.* (1997) An anti-adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes *in vitro* and depresses the development of pig adipose tissue. [J Anim Sci. 75 \(7\): 1791-7.](#)
2. Anderson, L.D. Jr *et al.* (1999) Enhancement of graft-versus-tumor activity and graft-

- versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. [Cancer Res. 59 \(7\): 1525-30.](#)
3. Lidington, E.A. *et al.* (2000) Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. [Blood. 96 \(8\): 2784-92.](#)
 4. Mason, J.C. *et al.* (2002) bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. [Am J Physiol Cell Physiol. 282: C578-87.](#)
 5. Mason, J.C. *et al.* (2002) Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. [Circ Res. 91 \(8\): 696-703.](#)
 6. Li, S.H. *et al.* (2004) C-reactive protein upregulates complement-inhibitory factors in endothelial cells. [Circulation. 109: 833-6.](#)
 7. Newcombe, J. *et al.* (2004) Infection with an avirulent phoP mutant of *Neisseria meningitidis* confers broad cross-reactive immunity. [Infect Immun. 72: 338-44.](#)
 8. Sancho, D. *et al.* (2006) CD69 targeting differentially affects the course of collagen-induced arthritis. [J Leukoc Biol. 80: 1233-41.](#)
 9. Hyams, C. *et al.* (2010) *Streptococcus pneumoniae* resistance to complement-mediated immunity is dependent on the capsular serotype. [Infect Immun. 78: 716-25.](#)
 10. Hung, M.C. *et al.* (2011) The *Neisseria meningitidis* Macrophage Infectivity Potentiator Protein Induces Cross-Strain Serum Bactericidal Activity and Is a Potential Serogroup B Vaccine Candidate. [Infect Immun. 79: 3784-91.](#)
 11. Lee, S.J. *et al.* (2012) Identification of a common immune signature in murine and human systemic Salmonellosis. [Proc Natl Acad Sci U S A. 109 \(13\): 4998-5003.](#)
 12. Hung MC *et al.* (2013) The adhesin complex protein (ACP) of *Neisseria meningitidis* is a new adhesin with vaccine potential. [MBio. 4 \(2\): pii: e00041-13.](#)
 13. Goh, Y.S. & MacLennan, C.A. (2013) Invasive African nontyphoidal *Salmonella* requires high levels of complement for cell-free antibody-dependent killing. [J Immunol Methods. 387 \(1-2\): 121-9.](#)
 14. Goh YS *et al.* (2016) Bactericidal Immunity to *Salmonella* in Africans and Mechanisms Causing Its Failure in HIV Infection. [PLoS Negl Trop Dis. 10 \(4\): e0004604.](#)
 15. Humbert MV *et al.* (2016) Vaccine Potential and Diversity of the Putative Cell Binding Factor (CBF, NMB0345/NEIS1825) Protein of *Neisseria meningitidis*. [PLoS One. 11 \(8\): e0160403.](#)
 16. Dierckx de Casterlé I *et al.* (2018) Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras. [Cancer Immunol Immunother. 67 \(4\): 589-603.](#)
 17. Valton, J. *et al.* (2018) A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies. [Sci Rep. 8 \(1\): 8972.](#)
 18. Dierckx de Casterlé, I. *et al.* (2018) Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras. [Cancer Immunol Immunother. 67 \(4\): 589-603.](#)
 19. Nganje, C.N. *et al.* (2019) PepN is a non-essential, cell wall-localized protein that contributes to neutrophil elastase-mediated killing of *Streptococcus pneumoniae*. [PLoS One. 14 \(2\): e0211632.](#)

20. Cuesta-Mateos, C. *et al.* (2020) CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia [Biomarker Research.8, 54.](#)

21. Mosti, L. *et al.* (2021) Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells. [Gene Ther. 28 \(9\): 602-12.](#)

22. Olivera-Ardid, S. *et al.* (2023) Removal of natural anti-αGal antibodies elicits protective immunity against Gram-negative bacterial infections. [Front Immunol. 14: 1232924.](#)

Storage	<p>Prior to reconstitution store at +4°C. Following reconstitution store at +4°C for 1 hour or aliquot and store at -70°C for longer.</p> <p>This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the product. Should this product contain a precipitate we recommend microcentrifugation before use.</p>
Guarantee	Guaranteed until date of expiry. Please see product label.
Health And Safety Information	Material Safety Datasheet documentation #10288 available at: https://www.bio-rad-antibodies.com/SDS/C12CA10288
Regulatory	For research purposes only

North & South America Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
---	---	--

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M420036:230706'

Printed on 18 Jan 2024